» Articles » PMID: 19344179

Mediating Tumor Targeting Efficiency of Nanoparticles Through Design

Overview
Journal Nano Lett
Specialty Biotechnology
Date 2009 Apr 7
PMID 19344179
Citations 434
Authors
Affiliations
Soon will be listed here.
Abstract

Here we systematically examined the effect of nanoparticle size (10-100 nm) and surface chemistry (i.e., poly(ethylene glycol)) on passive targeting of tumors in vivo. We found that the physical and chemical properties of the nanoparticles influenced their pharmacokinetic behavior, which ultimately determined their tumor accumulation capacity. Interestingly, the permeation of nanoparticles within the tumor is highly dependent on the overall size of the nanoparticle, where larger nanoparticles appear to stay near the vasculature while smaller nanoparticles rapidly diffuse throughout the tumor matrix. Our results provide design parameters for engineering nanoparticles for optimized tumor targeting of contrast agents and therapeutics.

Citing Articles

Plasma membrane-coated nanoparticles and membrane vesicles to orchestrate multimodal antitumor immunity.

Ito Y, Kasuya H, Kataoka M, Nakamura N, Yoshikawa T, Nakashima T J Immunother Cancer. 2025; 13(1).

PMID: 39864848 PMC: 11784344. DOI: 10.1136/jitc-2024-010005.


Optimal size and PEG coating of gold nanoparticles for prolonged blood circulation: a statistical analysis of published data.

Nevozhay D, Rauch R, Wang Z, Sokolov K Nanoscale Adv. 2025; 7(3):722-727.

PMID: 39811023 PMC: 11726233. DOI: 10.1039/d4na00782d.


The Effect of the Size of Gold Nanoparticle Contrast Agents on CT Imaging of the Gastrointestinal Tract and Inflammatory Bowel Disease.

Rosario-Berrios D, Pang A, Liu L, Maidment P, Kim J, Yoon S Bioconjug Chem. 2025; 36(2):233-244.

PMID: 39786354 PMC: 11839313. DOI: 10.1021/acs.bioconjchem.4c00507.


Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy.

Zhao Z, Fetse J, Mamani U, Guo Y, Li Y, Patel P Acta Biomater. 2024; 193:484-497.

PMID: 39716541 PMC: 11788053. DOI: 10.1016/j.actbio.2024.12.051.


In Vivo Gene Silencing and Cotreatment with Tamoxifen for Luminal A Breast Cancer Therapy.

Caribe Dos Santos Valle A, Silva F, Carneiro M, Espuche B, Tavares G, Bernardes E Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458966 PMC: 11509954. DOI: 10.3390/ph17101325.